Nasdaq
$4.05▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $10.5MShares out 2.6M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
19- 4d agoPre-market26.10.21 09:25filed10-Q/AEarnings#●●●#●●●
ADIAL PHARMACEUTICALS, INC.
Adial Pharmaceuticals has filed Amendment No. 1 to its Form 10-Q for the quarter ended June 30, 2026, in response to SEC staff comments. The amendment incorporates updates regarding purchase and exchange agreements entered into in September 2026 and quantifies the potential cash settlement for Series A Preferred Stock. As of August 12, 2026, the company had 2,625,890 shares of common stock outstanding.…more
$4.05+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 4d agoPre-market26.10.21 08:53filedS-3/AOffering
ADIAL PHARMACEUTICALS, INC.
Adial Pharmaceuticals has filed to register the resale of up to 25,148,970 shares of common stock issued or issuable in connection with the acquisition of Azora Therapeutics and the retirement of related debt. The registration covers shares issued as merger consideration, shares issuable upon conversion of Series A Preferred Stock, and shares issuable upon the exercise of pre-funded warrants. The company faces potential cash payment obligations to preferred stockholders if it fails to obtain necessary shareholder approval by December 11, 2026.…more
$4.05+0.00%vs prev closeView filingShare - 10.16After-hours26.10.17 06:16DEFA14AOther
ADIAL PHARMACEUTICALS, INC.
Adial Pharmaceuticals has further adjourned the vote on Proposals 3, 4, 5, and 6 at its 2026 Annual Meeting because it has not yet received Nasdaq's approval for its Initial Listing Application. The reconvened meeting for these specific proposals is now scheduled for October 26, 2026, at 8:30 a.m. Eastern Time.…more
$4.05+0.00%vs prev closeView filingShare
18 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.16Pre-market26.10.16 20:00#●●●#●●●
Adial Pharmaceuticals Appoints New Chief Scientist to Lead AT177 Development…more
Adial Pharmaceuticals has appointed Dr. David Rubenstein as Chief Scientist to oversee the development of its ulcerative colitis treatment, AT177. While the company aims to initiate human trials in 2027, the program remains in the early preclinical stage.…more
$4.05+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.30After-hours26.10.01 06:46
●●●●●●●● ●●●●● ●●●●●●
Adial Pharmaceuticals has granted stock options for 155,446 shares to a new employee as an inducement for employment under Nasdaq listing rules. This is a standard recruitment incentive and does not represent a material change in the company's financial position or stock outlook.…more
$4.05+0.00%vs prev close - 8.28After-hours26.08.29 05:52
●●●●●●●● ●●●●● ●●●●●●
Adial Pharmaceuticals has filed a prospectus for the potential resale of up to 25,148,970 shares of common stock by selling stockholders. This filing increases the potential supply of shares in the market, which may lead to dilution concerns for existing investors.…more
$4.05+0.00%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report